• RBC Capital Markets started coverage of Cytokinetics (NASDAQ:CYTK) with an outperform rating, citing valuation.
• “With shares down 50% since their January peak, we think the $3.6B opportunity driven by aficamten’s convenience, safety and efficacy in HCM is not being fully valued,” the investment bank wrote

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。